1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1151 articles with Genentech, Inc.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Heidi L. Wagner as senior vice president, government affairs and policy. Ms. Wagner joins GBT from Alexion Pharmaceuticals, where she was senior vice president, global government affairs.
Genentech is slashing 223 jobs at its South San Francisco headquarters, according to a Worker Adjustment and Retraining Notification posted on a California state government website. The layoffs will go into effect on Aug. 31, according to the WARN posting.
8/16/2018BioNTech, headquartered in Mainz, Germany, and Pfizer, based in New York City, signed a multi-year research-and-development deal to develop mRNA-based flu vaccines.
There are currently no FDA-approved treatments that help prevent severe reactions due to food allergies
This morning Genentech announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Xolair to treat exposure to those deadly food allergies.
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from the lead-in period of the GENESIS trial.
GlaxoSmithKline Chief Executive Officer Emma Walmsley has made another key appointment to her senior leadership team.
IGM Biosciences, a privately-held biotech company located in Mountain View, California, announced that Daniel S. Chen will be the company’s new chief medical officer. Chen arrives from Genentech/Roche, where he was most recently vice president, Global Head of Cancer Immunotherapy.
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134.
BioLineRx, based in Tel Aviv, Israel, and Merck & Co, based in Kenilworth, New Jersey, announced they are expanding their immuno-oncology collaboration.
Genentech and Horizon Pharma were the only two biopharma companies that made People’s 2018 list of “50 Companies That Care,” a list that highlights how a company makes a difference in the lives of its employees, as well as the communities those companies call home.
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE® Technology
Subcutaneous administration using Halozyme's proprietary ENHANZE® drug-delivery technology in combination with chemotherapy.
Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS)...
Nearly four months after acquiring 100 percent control of its consumer health unit, GlaxoSmithKline Chairman Philip Hampton may be pushing for the business to become a standalone entity apart from its pharma and vaccines division, according to The Financial Times.
Genentech to Present New Data Demonstrating the Breadth and Depth of Its Alzheimer’s Program at the Upcoming Alzheimer's Association International Conference (AAIC)
Late-breaking Phase II exploratory analysis of investigational crenezumab to show impact on beta amyloid oligomer levels in cerebral spinal fluid (CSF)
Genentech’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in the Initial Treatment of People With Advanced Lung Cancer
Genentech announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS)
FDA Grants Breakthrough Therapy Designation for Genentech’s TECENTRIQ in Combination With Avastin as First-Line Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Genentech announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for TECENTRIQ® (atezolizumab)
Two well-known pharmaceutical companies made Fortune Magazine’s 2018 top 100 Best Workplaces for Millennials.
Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu
Baloxavir marboxil – an investigational oral, single-dose antiviral – is the first flu medicine with a novel proposed mechanism of action in nearly 20 years and to demonstrate significant efficacy in high-risk populations
With flu season fast approaching, Genentech has some good news for people who are at high risk of complications from the illness.